Mats Wahlstrom
Mats Wahlstrom's purchase track record
Mats Wahlstrom has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/15/2026 | TLSI | $152K | +96.6% | pending | — |
| 11/20/2024 | TLSI | $70K | +40.5% | +33.7% | -1.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TriSalus Stock Rises After FDA Clears TriNav Advance. TriSalus Life Sciences shares climbed 15.6% following FDA clearance for its TriNav Advance product. This regulatory approval marks a significant milestone for the company's pipeline. The stock is currently testing key support levels after the recent price movement.
Transaction History
| CHRS | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 | View on chart |
| TLSI | ▲ Buy | Open Market | 60,000 | $152K | 5/15/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 37,602 | $0 | 5/14/2026 | View on chart |
| TLSI | ▲ Buy | Grant | 34,226 | $0 | 5/14/2026 | View on chart |
| CHRS | ▼ Sell | Open Market | 99,988 | $74K | 5/23/2025 | View on chart |
| TLSI | ▲ Buy | Grant | 25,188 | $100K | 12/17/2024 | View on chart |
| TLSI | ▲ Buy | Open Market | 5,000 | $23K | 11/22/2024 | View on chart |
| TLSI | ▲ Buy | Open Market | 8,687 | $39K | 11/21/2024 | View on chart |
| TLSI | ▲ Buy | Open Market | 2,040 | $8K | 11/20/2024 | View on chart |
| CHRS | ▼ Sell | Gift | 99,988 | $0 | 2/9/2024 | View on chart |
| CHRS | ▼ Sell | Gift | 99,988 | $0 | 2/9/2024 | View on chart |
| CHRS | ▲ Buy | Option Exercise | 14,997 | $25K | 2/1/2024 | View on chart |
| CHRS | ▲ Buy | Option Exercise | 44,991 | $75K | 2/1/2024 | View on chart |
| CHRS | ▲ Buy | Grant | 29,994 | $63K | 2/28/2022 | View on chart |
| CHRS | ▲ Buy | Grant | 10,006 | $116K | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets
Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.